Navigation Links
Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Date:5/15/2009

Completion of enrollment keeps Company on track to report primary study results in third quarter of this year

ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 influenza season. This clinical trial represents another step in the development of Novavax's VLP seasonal influenza vaccine, allowing further evaluation of safety and immunogenicity of a broad range of vaccine doses against a new set of influenza strains. As announced in December of 2008, the first Phase II study evaluated a trivalent VLP vaccine against the seasonal influenza strains that circulated in the 2005-2006 influenza season.

Specifically, this new study is evaluating the safety and immunogenicity of the 2008-2009 influenza vaccine in approximately 220 healthy adults between the ages of 18 and 49 years. Subjects have received a single injection of either a placebo or the VLP vaccine at doses of 15 mcg or 60 mcg per strain. The results of this study will be used to help select a dose for further evaluation in a clinical trial involving adults 65 years of age and older later this year and in a subsequent Phase III efficacy study.

"Enrollment of this second Phase II clinical trial represents another important developmental milestone for our VLP seasonal influenza vaccine program," said Dr. Rahul Singhvi, President and CEO of Novavax. "This study provides the opportunity to evaluate the safety and immunogenicity of our VLP vaccine against a new set of influenza strains, further strengthening our growing
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... LONDON , October 20, 2014 ... study of its novel, low volume bowel preparation, NER1006, ... of the American College of Gastroenterology (ACG), ... end point of stool weight and co-primary endpoint of ... efficacy with NER1006 vs. MOVIPREP ® in screening ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... - Two Large-Scale Analyses Have Conflicting Results -, ... decline,in memory and thinking processes among placebo groups ... to show the effectiveness,of new Alzheimer therapies, according ... Association International Conference on Alzheimer,s,Disease (ICAD 2008) in ...
... 25 Genaera,Corporation (Nasdaq: GENR ) ... (PK) data and new preclinical data on ... treatment of type 2,diabetes and obesity, during ... in Arlington, Virginia. Dr. Michael McLane, Vice ...
Cached Medicine Technology:Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 3Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 4Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 5Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 2Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 3Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 4Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit 5
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian cancer ... think outside the bra. She doesn’t try to hide her ... about women’s other lady parts. , "We have won the ... pink and everybody knows what you’re talking about,” Jess-Huff points ... not been won when it comes to gynecologic cancers. It ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
(Date:10/20/2014)... 20, 2014 Rockynol Retirement Community ... on Oct. 14. The $11 million project will include ... a cooked-to-order kitchen with full-service restaurant style dining. , ... for first class Assisted Living apartments,” said Kara Hanzie, ... the highest quality of care and this investment is ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... discovered the genetic factors that make some mosquitoes resistant ... the mosquitos immune system is the key to their finding. ... parasite that causes malaria, a biochemical reaction is triggered that ... on to the parasites surface and targeting it for termination, ...
... a teenager Scot of severe asthma. ,Fifteen-year-old ... had to give up sports and physical education lessons at ... had read somewhere about the benefits of playing wind instruments ... one. ,Being a proud Glasgow-born Scot, David ...
... received the world's first face transplant 18 months ago said Friday ... in the mirror with a combination of sadness and wonder. ... have a face, a smile, facial expressions which allow them to ... an interview published in Saturday's edition of Le Monde. ...
... the allegedly substandard Chinese products make constant headlines in the ... crackdown. ,For starters it has suspended the sale ... arthritis. ,In the past week alone, a former ... sentenced to death on bribery charges, and it was announced ...
... in OK! magazine's list of 'most influential' celebrities. ... the 'beauty queen' category for her 'refreshing girl-next-door look' ... Beyonce and Jennifer Lopez behind. ,According to ... celebrities in six categories including beauty queens, style setters, ...
... has openly confessed that she had sex with former boyfriend Justin ... she was married. ,"I've only slept with one person ... relationship with Justin, and I thought he was the one. But ... The most painful thing I have ever experienced was that ...
Cached Medicine News:Health News:Genetic Factors Behind Mosquitoes Resistance to Malaria Identified 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2Health News:China Cracks the Whip Against Drug Manufacturers Who Fail Quality Norms 2
... The CineScan A/B represent a true ... analog image with technology and diagnostic capability ... in the vitreous. Adjust the gain up ... would be invisible at a standard 90db ...
EchoScan US-2500 is available in a single configuration or in combination with the A scan for maximum cost efficiency....
... in the 21st century requires ... Alcon® UltraScan® imaging system responds ... at clinical echographic needs in ... permits step-by-step processing to collect ...
PremierEdge™ MVR Knives. Angled....
Medicine Products: